JP2007506442A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007506442A5 JP2007506442A5 JP2006533538A JP2006533538A JP2007506442A5 JP 2007506442 A5 JP2007506442 A5 JP 2007506442A5 JP 2006533538 A JP2006533538 A JP 2006533538A JP 2006533538 A JP2006533538 A JP 2006533538A JP 2007506442 A5 JP2007506442 A5 JP 2007506442A5
- Authority
- JP
- Japan
- Prior art keywords
- expression
- array
- cancer
- ckap4
- tissue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000014509 gene expression Effects 0.000 claims 26
- 102100010221 CKAP4 Human genes 0.000 claims 10
- 101700076376 CKAP4 Proteins 0.000 claims 10
- 229920000023 polynucleotide Polymers 0.000 claims 10
- 239000002157 polynucleotide Substances 0.000 claims 10
- 210000001519 tissues Anatomy 0.000 claims 10
- 229940121647 EGFR inhibitors Drugs 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 7
- 102100016486 CCND3 Human genes 0.000 claims 6
- 101700079292 CCND3 Proteins 0.000 claims 6
- 101710007887 DHFR Proteins 0.000 claims 6
- 102100005838 DHFR Human genes 0.000 claims 6
- 102100008899 GPX2 Human genes 0.000 claims 6
- 101700040033 GPX2 Proteins 0.000 claims 6
- 101710017500 MitHPPK/DHPS Proteins 0.000 claims 6
- 102100018287 NKX2-1 Human genes 0.000 claims 6
- 108010057966 Thyroid Nuclear Factor 1 Proteins 0.000 claims 6
- 230000000875 corresponding Effects 0.000 claims 6
- 239000000523 sample Substances 0.000 claims 6
- 229920000160 (ribonucleotides)n+m Polymers 0.000 claims 5
- 102000004161 Claudin-4 Human genes 0.000 claims 5
- 108090000601 Claudin-4 Proteins 0.000 claims 5
- 101700031267 DPYD Proteins 0.000 claims 5
- 102100005049 DPYD Human genes 0.000 claims 5
- 102100010285 EMP1 Human genes 0.000 claims 5
- 101700041125 EMP1 Proteins 0.000 claims 5
- 101710030892 FLT1 Proteins 0.000 claims 5
- 102100006565 FLT1 Human genes 0.000 claims 5
- 108090001126 FURIN Proteins 0.000 claims 5
- 102000004961 Furin Human genes 0.000 claims 5
- 102100014894 MMP2 Human genes 0.000 claims 5
- 101700060512 MMP2 Proteins 0.000 claims 5
- 102100013434 MTA1 Human genes 0.000 claims 5
- 101700056668 MTA1 Proteins 0.000 claims 5
- 101700048958 MYCL Proteins 0.000 claims 5
- 102100018883 MYCL Human genes 0.000 claims 5
- 102100016136 RASSF1 Human genes 0.000 claims 5
- 101710037979 RASSF1 Proteins 0.000 claims 5
- 102100013397 STAT5B Human genes 0.000 claims 5
- 101710035391 STAT5B Proteins 0.000 claims 5
- 102100006947 TAGLN Human genes 0.000 claims 5
- 101710025884 TAGLN Proteins 0.000 claims 5
- 102100006014 TIMP2 Human genes 0.000 claims 5
- 101700065146 TIMP2 Proteins 0.000 claims 5
- 101700071914 TMN8 Proteins 0.000 claims 5
- 108010085257 X-Linked Inhibitor of Apoptosis Protein Proteins 0.000 claims 5
- 102100010212 XIAP Human genes 0.000 claims 5
- 238000001574 biopsy Methods 0.000 claims 5
- 238000003752 polymerase chain reaction Methods 0.000 claims 5
- 102000012162 60S acidic ribosomal protein P0 Human genes 0.000 claims 4
- 108050002744 60S acidic ribosomal protein P0 Proteins 0.000 claims 4
- KJWZYMMLVHIVSU-IYCNHOCDSA-N 7-[(1R,2R)-2-[(E,3S)-3-hydroxyoct-1-enyl]-3,5-dioxocyclopentyl]heptanoic acid Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](CCCCCCC(O)=O)C(=O)CC1=O KJWZYMMLVHIVSU-IYCNHOCDSA-N 0.000 claims 4
- 102100020486 CCN4 Human genes 0.000 claims 4
- 101710013050 CCN4 Proteins 0.000 claims 4
- 101700010580 FLO11 Proteins 0.000 claims 4
- 102100011898 FOLR1 Human genes 0.000 claims 4
- 101700050183 FOLR1 Proteins 0.000 claims 4
- 102100014738 IGFBP3 Human genes 0.000 claims 4
- 101710031099 IGFBP3 Proteins 0.000 claims 4
- 102100017933 IGFBP6 Human genes 0.000 claims 4
- 101710031085 IGFBP6 Proteins 0.000 claims 4
- 102100006844 MMP9 Human genes 0.000 claims 4
- 101700067851 MMP9 Proteins 0.000 claims 4
- 102100006037 MUC1 Human genes 0.000 claims 4
- 101700052761 MUC1 Proteins 0.000 claims 4
- 101710018349 PDGFRA Proteins 0.000 claims 4
- 102100013410 PGK1 Human genes 0.000 claims 4
- 101700059663 PGK1 Proteins 0.000 claims 4
- 102100019317 CTSH Human genes 0.000 claims 3
- 101710041508 CTSH Proteins 0.000 claims 3
- 101700018903 E2F1 Proteins 0.000 claims 3
- 102100016365 E2F1 Human genes 0.000 claims 3
- 101700058245 E2FB Proteins 0.000 claims 3
- 101710030424 EPHX1 Proteins 0.000 claims 3
- 102100017903 EPHX1 Human genes 0.000 claims 3
- 101700025368 ERBB2 Proteins 0.000 claims 3
- 102100016662 ERBB2 Human genes 0.000 claims 3
- 102100006140 FOXA1 Human genes 0.000 claims 3
- 101700084156 FOXA1 Proteins 0.000 claims 3
- 102100014263 IGF1R Human genes 0.000 claims 3
- 101700025802 IGF1R Proteins 0.000 claims 3
- 102100005749 KRT17 Human genes 0.000 claims 3
- 101710026199 KRT17 Proteins 0.000 claims 3
- 102100009095 LAMC2 Human genes 0.000 claims 3
- 101700017755 LAMC2 Proteins 0.000 claims 3
- 102100016819 MMP11 Human genes 0.000 claims 3
- 101700081066 MMP11 Proteins 0.000 claims 3
- 101710005210 MRPL19 Proteins 0.000 claims 3
- 102100013280 MTMR11 Human genes 0.000 claims 3
- 101710038778 MTMR11 Proteins 0.000 claims 3
- 229920000272 Oligonucleotide Polymers 0.000 claims 3
- 101710018346 PDGFRB Proteins 0.000 claims 3
- 101710037934 QRSL1 Proteins 0.000 claims 3
- 102100013620 RPL19 Human genes 0.000 claims 3
- 101710004264 RPL19 Proteins 0.000 claims 3
- 102100015206 VEGFC Human genes 0.000 claims 3
- 101700082383 VEGFC Proteins 0.000 claims 3
- 102100001605 AKAP12 Human genes 0.000 claims 2
- 101710011886 AKAP12 Proteins 0.000 claims 2
- 229920002287 Amplicon Polymers 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 229920002676 Complementary DNA Polymers 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 2
- 102000004965 antibodies Human genes 0.000 claims 2
- 108090001123 antibodies Proteins 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 239000002299 complementary DNA Substances 0.000 claims 2
- 102000017256 epidermal growth factor-activated receptor activity proteins Human genes 0.000 claims 2
- 108040009258 epidermal growth factor-activated receptor activity proteins Proteins 0.000 claims 2
- 238000010195 expression analysis Methods 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010017758 Gastric cancer Diseases 0.000 claims 1
- 229920002459 Intron Polymers 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 claims 1
- 108009000071 Non-small cell lung cancer Proteins 0.000 claims 1
- 102100019667 STAT3 Human genes 0.000 claims 1
- 108010017324 STAT3 Transcription Factor Proteins 0.000 claims 1
- 238000004166 bioassay Methods 0.000 claims 1
- 201000011231 colorectal cancer Diseases 0.000 claims 1
- 239000011521 glass Substances 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 238000003364 immunohistochemistry Methods 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 238000004393 prognosis Methods 0.000 claims 1
- 238000000575 proteomic Methods 0.000 claims 1
- 238000003757 reverse transcription PCR Methods 0.000 claims 1
- 150000003384 small molecules Chemical group 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
Claims (42)
- 被験体がEGFRインヒビターを用いる処置に応答する可能性を予測するのを補助するための方法であって、該方法は、患者から得られる癌細胞を含む生物学的サンプルにおいて、1種以上の予後RNA転写物またはそれらの発現産物の発現レベルを決定する工程を包含し、ここで該予後転写物は、以下、:hCRA a;LAMC2;B2M;STAT5B;LMYC;CKAP4;TAGLN;Furin;DHFR;CCND3;TITF1;FUS;FLT1;TIMP2;RASSF1;WISP1;VEGFC;GPX2;CTSH;AKAP12;APC;RPL19;IGFBP6;Bak;CyclinG1;Hepsin1;MMP2;XIAP;MUC1;STMY3;PDGFRb;GSTp;p53R2;DPYD;IGFBP3;MMP9;RRM;KRT17;PDGFRa;EPHX1;E2F1;HNF3A;mGST1;STAT3;IGF1R;EGFR;cdc25A;RPLPO;YB−1;CKAP4;Kitlng;HER2;Surfact A;BTC;PGK1;MTA1;FOLR1;Claudin 4;EMP1からなる群より選択される、1種以上の遺伝子の転写物であって、ここで、
(a)hCRA a;LAMC2;STAT5B;CKAP4;TAGLN;Furin;FUS;FLT1;TIMP2;RASSF1;WISP1;VEGFC;GPX2;AKAP12;RPL19;IGFBP6;MMP2;STMY3;PDGFRb;GSTp;IGFBP3;MMP9;KRT17;PDGFRa;IGF1R;cdc25A;RPLPO;YB−1;CKAP4、EMP1または対応する発現産物の1種以上の上昇した発現の全ての単位について、該被験体は、EGFRインヒビターを用いる処置に応答する可能性が減少することが予期される方法であって、そして、
(b)B2M;LMYC;DHFR;CCND3;TITF1;CTSH;APC;Bak;CyclinG1;Hepsin1;XIAP;MUC1;p53R2;DPYD;RRM;EPHX1;E2F1;HNF3A;mGST1;STAT3;EGFR;Kitlng;HER2;Surfact A;BTC;PGK1;MTA1;FOLR1;Claudin 4または対応する発現産物の1種以上の上昇した発現の全ての単位について、該被験体は、EGFRインヒビターを用いる処置に応答する可能性が増加することが予期される、方法。 - 前記被験体が、ヒト患者である、請求項1に記載の方法。
- 前記予後転写物またはそれらの発現産物のうちの少なくとも2種の発現レベルを決定する工程を包含する、請求項2に記載の方法。
- 前記予後転写物またはそれらの発現産物のうちの少なくとも5種の発現レベルを決定する工程を包含する、請求項2に記載の方法。
- 前記予後転写物またはそれらの発現産物のすべての発現レベルを決定する工程を包含する、請求項2に記載の方法。
- 前記癌が、卵巣癌、結腸癌、膵臓癌、非小細胞肺癌、乳癌、ならびに頭部癌および頸部癌からなる群より選択される、請求項2に記載の方法。
- 前記生物学的サンプルが、癌細胞を含む組織サンプルである、請求項2に記載の方法。
- 前記組織が、固定組織、パラフィン包埋組織、または新鮮な組織、または凍結組織である、請求項7に記載の方法。
- 前記組織が、細針生検、針生検、または他の型の生検に由来する、請求項7に記載の方法。
- 前記組織サンプルが、細針吸引、気管支洗浄、または経気管支生検によって得られる、請求項7に記載の方法。
- 前記予後RNA転写物の発現レベルが、RT−PCRによって決定される、請求項1に記載の方法。
- 前記発現産物の発現レベルが、免疫組織化学によって決定される、請求項1に記載の方法。
- 前記発現産物の発現レベルが、プロテオミクス技術によって決定される、請求項1に記載の方法。
- 予後RNA転写物またはそれらの発現産物を測定するためのアッセイが、キットの形態で提供される、請求項1に記載の方法。
- 前記EGFRインヒビターが、抗体または抗体フラグメントである、請求項1に記載の方法。
- 前記EGFRインヒビターが、低分子である、請求項1に記載の方法。
- 固体表面上に固定化された、以下:hCRA a;LAMC2;B2M;STAT5B;LMYC;CKAP4;TAGLN;Furin;DHFR;CCND3;TITF1;FUS;FLT1;TIMP2;RASSF1;WISP1;VEGFC;GPX2;CTSH;AKAP12;APC;RPL19;IGFBP6;Bak;CyclinG1;Hepsin1;MMP2;XIAP;MUC1;STMY3;PDGFRb;GSTp;p53R2;DPYD;IGFBP3;MMP9;RRM;KRT17;PDGFRa;EPHX1;E2F1;HNF3A;mGST1;STAT3;IGF1R;EGFR;cdc25A;RPLPO;YB−1;CKAP4;Kitlng;HER2;Surfact A;BTC;PGK1;MTA1;FOLR1;Claudin 4;EMP1の1種以上の遺伝子に対してハイブリダイズするポリヌクレオチドを含む、アレイ。
- 複数の前記遺伝子にハイブリダイズするポリヌクレオチドを含む、請求項17に記載のアレイ。
- 前記遺伝子のうちの少なくとも5種にハイブリダイズするポリヌクレオチドを含む、請求項18に記載のアレイ。
- 前記遺伝子のうちの少なくとも10種にハイブリダイズするポリヌクレオチドを含む、請求項18に記載のアレイ。
- 前記遺伝子のうちの少なくとも15種にハイブリダイズするポリヌクレオチドを含む、請求項18に記載のアレイ。
- 前記遺伝子の全てにハイブリダイズするポリヌクレオチドを含む、請求項18に記載のアレイ。
- 同一の遺伝子にハイブリダイズする2種以上のポリヌクレオチドを含む、請求項18に記載のアレイ。
- 前記ポリヌクレオチドのうちの少なくとも1種が、イントロンベースの配列を含み、その発現は、対応するエクソン配列の発現と関連する、請求項18に記載のアレイ。
- 前記ポリヌクレオチドが、cDNAである、請求項17に記載のアレイ。
- 前記cDNAが、約500〜約5000塩基長である、請求項25に記載のアレイ。
- 前記ポリヌクレオチドが、オリゴヌクレオチドである、請求項17に記載のアレイ。
- 前記オリゴヌクレオチドが、約20〜約80塩基長である、請求項27に記載のアレイ。
- 約330,000オリゴヌクレオチドを含む、請求項28に記載のアレイ。
- 前記固体表面が、ガラスである、請求項17に記載のアレイ。
- 患者についての個別のゲノムプロファイルを調製する方法であって、以下:
(a)該患者から得られた癌細胞から抽出されたRNAを、遺伝子発現分析に供する工程:
(b)以下、:hCRA a;LAMC2;B2M;STAT5B;LMYC;CKAP4;TAGLN;Furin;DHFR;CCND3;TITF1;FUS;FLT1;TIMP2;RASSF1;WISP1;VEGFC;GPX2;CTSH;AKAP12;APC;RPL19;IGFBP6;Bak;CyclinG1;Hepsin1;MMP2;XIAP;MUC1;STMY3;PDGFRb;GSTp;p53R2;DPYD;IGFBP3;MMP9;RRM;KRT17;PDGFRa;EPHX1;E2F1;HNF3A;mGST1;STAT3;IGF1R;EGFR;cdc25A;RPLPO;YB−1;CKAP4;Kitlng;HER2;Surfact A;BTC;PGK1;MTA1;FOLR1、EMP1からなる群より選択される1種以上の遺伝子の、組織における発現レベルを決定する工程であって、ここで、該発現レベルは、コントロール遺伝子(単数または複数)に対して標準化され、そして必要に応じて、対応する癌関連組織セットにおいて見出される量と比較される、工程:ならびに
(c)該遺伝子発現分析によって得られたデータを要約する報告を作成する工程、を包含する方法。 - 前記癌細胞が、固形腫瘍から得られる、請求項31に記載の方法。
- 上記固形腫瘍が、乳癌、卵巣癌、胃癌、結腸直腸癌、膵臓癌、および肺癌からなる群より選択される、請求項32に記載の方法。
- 前記癌細胞が、固定サンプル、パラフィン包埋生検サンプルから得られる、請求項31に記載の方法。
- 前記RNAが、フラグメント化されている、請求項34に記載の方法。
- 前記データは、前記患者がEGFRインヒビターを用いる処置に応答する可能性の予想を含むことを意図される、請求項31に記載の方法。
- 前記データは、前記患者の処置様式についての推奨を含むことを意図される、請求項36に記載の方法。
- 以下、B2M;LMYC;DHFR;CCND3;TITF1;CTSH;APC;Bak;CyclinG1;Hepsin1;XIAP;MUC1;p53R2;DPYD;RRM;EPHX1;E2F1;HNF3A;mGST1;STAT3;EGFR;Kitlng;HER2;Surfact A;BTC;PGK1;MTA1;FOLR1;Claudin 4または対応する発現産物の1種以上の発現の上昇が決定される場合、前記報告が、前記被験体は、EGFRインヒビターを用いる処置に応答する可能性が増加するという予測を含む、請求項31に記載の方法。
- 前記患者は、EGFRインヒビターを用いて処置されることを意図される、請求項38に記載の方法。
- 以下、hCRA a;LAMC2;B2M;STAT5B;LMYC;CKAP4;TAGLN;Furin;DHFR;CCND3;TITF1;FUS;FLT1;TIMP2;RASSF1;WISP1;VEGFC;GPX2;CTSH;AKAP12;APC;RPL19;IGFBP6;Bak;CyclinG1;Hepsin1;MMP2;XIAP;MUC1;STMY3;PDGFRb;GSTp;p53R2;DPYD;IGFBP3;MMP9;RRM;KRT17;PDGFRa;EPHX1;E2F1;HNF3A;mGST1;STAT3;IGF1R;EGFR;cdc25A;RPLPO;YB−1;CKAP4;Kitlng;HER2;Surfact A;BTC;PGK1;MTA1;FOLR1;Claudin 4;EMP1からなる群より選択される遺伝子を、ポリメラーゼ連鎖反応(PCR)により増幅するための方法であって、表3に列挙される対応するアンプリコン、および表4に列挙される対応するプライマープローブセットを使用して、該PCRを実行する工程を包含する、方法。
- 表4に列挙される、PCRプライマープローブセット。
- 表3に列挙される、PCRアンプリコン。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47490803P | 2003-05-30 | 2003-05-30 | |
PCT/US2004/017215 WO2004111273A2 (en) | 2003-05-30 | 2004-05-28 | Gene expression markers for response to egfr inhibitor drugs |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2007506442A JP2007506442A (ja) | 2007-03-22 |
JP2007506442A5 true JP2007506442A5 (ja) | 2007-07-05 |
Family
ID=33551513
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006533538A Pending JP2007506442A (ja) | 2003-05-30 | 2004-05-28 | Egfr阻害薬への応答に関する遺伝子発現マーカー |
Country Status (6)
Country | Link |
---|---|
US (2) | US20050164218A1 (ja) |
EP (2) | EP2226396A1 (ja) |
JP (1) | JP2007506442A (ja) |
AU (2) | AU2004248140A1 (ja) |
CA (1) | CA2527321A1 (ja) |
WO (1) | WO2004111273A2 (ja) |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050059012A1 (en) * | 2002-07-31 | 2005-03-17 | Daniel Afar | Diagnosis of ZD1839 resistant tumors |
US20050267689A1 (en) * | 2003-07-07 | 2005-12-01 | Maxim Tsypin | Method to automatically identify peak and monoisotopic peaks in mass spectral data for biomolecular applications |
WO2005011520A2 (en) | 2003-07-25 | 2005-02-10 | Dexcom, Inc. | Oxygen enhancing membrane systems for implantable devices |
US8017321B2 (en) | 2004-01-23 | 2011-09-13 | The Regents Of The University Of Colorado, A Body Corporate | Gefitinib sensitivity-related gene expression and products and methods related thereto |
JP5422120B2 (ja) * | 2004-05-27 | 2014-02-19 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド,ア ボディー コーポレイト | 癌患者による上皮成長因子受容体阻害薬に対する臨床転帰の予測方法 |
CA2569520C (en) | 2004-06-04 | 2023-03-14 | Genentech, Inc. | Kras mutations for identifying colorectal tumors responsive to cetuximab or panitumumab |
WO2006101925A2 (en) | 2005-03-16 | 2006-09-28 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors |
US8383357B2 (en) | 2005-03-16 | 2013-02-26 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors |
WO2006107854A2 (en) | 2005-04-01 | 2006-10-12 | Amgen Inc. | Epidermal growth factor receptor gene copy number |
EP2083088A3 (en) * | 2005-04-07 | 2009-10-14 | Novartis Vaccines and Diagnostics, Inc. | Cancer-related genes |
KR20080003422A (ko) * | 2005-04-14 | 2008-01-07 | 메르크 파텐트 게엠베하 | 종양 조직 내의 egfr 유전자의 증가된 복제수에 기초한항-egfr 항체 치료 |
US20060252082A1 (en) * | 2005-05-04 | 2006-11-09 | University Of South Florida | Predicting treatment response in cancer subjects |
PL1913157T5 (pl) * | 2005-06-28 | 2017-09-29 | Genentech Inc | Mutacje EGFR i KRAS do prognozowania reakcji pacjenta na leczenie inhibitorem EGFR |
ES2374450T3 (es) * | 2005-09-20 | 2012-02-16 | OSI Pharmaceuticals, LLC | Marcadores biológicos predictivos de respuesta anticancerígena para inhibidores de cinasa del receptor del factor de crecimiento 1 similar a insulina. |
CN104749378A (zh) * | 2006-02-16 | 2015-07-01 | 文塔纳医疗系统公司 | 用于癌症预后和病理分期的试剂和方法 |
US20070207467A1 (en) * | 2006-03-01 | 2007-09-06 | Ming Xu | Detection of lymph node metastasis from gastric carcinoma |
JP2007252312A (ja) * | 2006-03-24 | 2007-10-04 | Japan Health Science Foundation | 上皮成長因子受容体−チロシンキナーゼ阻害剤に対する肺ガンの感度測定方法および肺ガン治療剤のスクリーニング方法 |
US8024282B2 (en) * | 2006-03-31 | 2011-09-20 | Biodesix, Inc. | Method for reliable classification of samples in clinical diagnostics using an improved method of classification |
US7858390B2 (en) * | 2006-03-31 | 2010-12-28 | Biodesix, Inc. | Selection of colorectal cancer patients for treatment with drugs targeting EGFR pathway |
US7858389B2 (en) * | 2006-03-31 | 2010-12-28 | Biodesix, Inc. | Selection of non-small-cell lung cancer patients for treatment with monoclonal antibody drugs targeting EGFR pathway |
US7736905B2 (en) * | 2006-03-31 | 2010-06-15 | Biodesix, Inc. | Method and system for determining whether a drug will be effective on a patient with a disease |
US7906342B2 (en) | 2006-03-31 | 2011-03-15 | Biodesix, Inc. | Monitoring treatment of cancer patients with drugs targeting EGFR pathway using mass spectrometry of patient samples |
US7867775B2 (en) * | 2006-03-31 | 2011-01-11 | Biodesix, Inc. | Selection of head and neck cancer patients for treatment with drugs targeting EGFR pathway |
EP3399450A1 (en) | 2006-05-18 | 2018-11-07 | Caris MPI, Inc. | System and method for determining individualized medical intervention for a disease state |
US8768629B2 (en) | 2009-02-11 | 2014-07-01 | Caris Mpi, Inc. | Molecular profiling of tumors |
US20070281305A1 (en) * | 2006-06-05 | 2007-12-06 | Sean Wuxiong Cao | Detection of lymph node metastasis from gastric carcinoma |
ES2372217T3 (es) * | 2006-09-12 | 2012-01-17 | Genentech, Inc. | Procedimientos y composiciones para el diagnóstico y tratamiento del cáncer de pulmón utilizando el gen de pdgfra, kit o kdr como marcador genético. |
CA2680326A1 (en) | 2007-03-13 | 2008-09-18 | Amgen Inc. | K-ras mutations and anti-egfr antibody therapy |
JP5240739B2 (ja) | 2007-04-13 | 2013-07-17 | オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー | キナーゼ阻害剤に対する抗癌応答を予測する生物学的マーカー |
WO2009023172A2 (en) * | 2007-08-09 | 2009-02-19 | The Johns Hopkins University | Predictions of responsiveness to egfr inhibitors |
JP2010535518A (ja) * | 2007-08-14 | 2010-11-25 | エフ.ホフマン−ラ ロシュ アーゲー | Egfr阻害剤治療のための予測マーカー |
CN101802221A (zh) * | 2007-08-14 | 2010-08-11 | 霍夫曼-拉罗奇有限公司 | Egfr抑制剂治疗的预测性标记物 |
MX2010001578A (es) * | 2007-08-14 | 2010-03-15 | Hoffmann La Roche | Marcador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico. |
BRPI0814354A2 (pt) * | 2007-08-14 | 2015-01-20 | Hoffmann La Roche | Marcador preditivo para tratamento com inibidor de egfr |
DK2176430T5 (da) * | 2007-08-14 | 2013-09-08 | Hoffmann La Roche | Indikator-markør til EGFR-inhibitor-behandling |
MX2010001573A (es) * | 2007-08-14 | 2010-03-15 | Hoffmann La Roche | Marcador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico. |
WO2009045361A2 (en) | 2007-10-03 | 2009-04-09 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
CA2694356A1 (en) | 2007-10-03 | 2009-04-09 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
EP2288727B1 (en) * | 2008-05-14 | 2013-07-10 | Genomic Health, Inc. | Predictors of patient response to treatment with egf receptor inhibitors |
WO2010015538A2 (en) * | 2008-08-05 | 2010-02-11 | F. Hoffmann-La Roche Ag | Predictive marker for egfr inhibitor treatment |
WO2010015536A1 (en) * | 2008-08-05 | 2010-02-11 | F. Hoffmann-La Roche Ag | Predictive marker for egfr inhibitor treatment |
WO2010015535A1 (en) * | 2008-08-05 | 2010-02-11 | F. Hoffmann-La Roche Ag | Predictive marker for egfr inhibitor treatment |
EP2347009A4 (en) * | 2008-10-14 | 2012-05-30 | Caris Mpi Inc | GENE AND GENE EXPRESSED TARGET PROTEINS FOR THE PRESENTATION OF BIOMARKERS AND SIGNATURES BY TUMOR TYPE |
EP2342355A4 (en) * | 2008-10-29 | 2012-06-27 | Beaumont Hospital William | METHODS OF USING BIOMARKERS |
WO2011109440A1 (en) | 2010-03-01 | 2011-09-09 | Caris Life Sciences Luxembourg Holdings | Biomarkers for theranostics |
EP3181705A1 (en) | 2008-11-12 | 2017-06-21 | Caris Life Sciences Switzerland Holdings GmbH | Methods and systems of using exosomes for determining phenotypes |
WO2010064702A1 (ja) * | 2008-12-05 | 2010-06-10 | 国立大学法人 東京大学 | 癌の予後を予測するためのバイオマーカー |
JP2012519170A (ja) * | 2009-02-26 | 2012-08-23 | オーエスアイ・ファーマシューティカルズ,エルエルシー | 生体内の腫瘍細胞のemtステータスをモニターするためのinsitu法 |
JP2013520681A (ja) * | 2010-02-24 | 2013-06-06 | バイオデシックス・インコーポレイテッド | 質量スペクトル分析を用いた、治療薬投与のための癌患者のセレクション |
WO2011109584A2 (en) | 2010-03-03 | 2011-09-09 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
US20110275644A1 (en) | 2010-03-03 | 2011-11-10 | Buck Elizabeth A | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
WO2011127219A1 (en) | 2010-04-06 | 2011-10-13 | Caris Life Sciences Luxembourg Holdings | Circulating biomarkers for disease |
CA2824877A1 (en) | 2011-01-28 | 2012-08-02 | Biodesix, Inc. | Predictive test for selection of metastatic breast cancer patients for hormonal and combination therapy |
WO2012116040A1 (en) | 2011-02-22 | 2012-08-30 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma |
WO2012149014A1 (en) | 2011-04-25 | 2012-11-01 | OSI Pharmaceuticals, LLC | Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment |
BR112014004762A2 (pt) | 2011-08-31 | 2018-06-19 | Genentech Inc | métodos de determinação da sensibilidade de crescimento de célula tumoral á inibição por um inibidor de quinase de egfr, de identificação de um paciente com câncer que provavelmente irá se beneficiar do tratamento com um inibidor de efgr, de tratamento de um câncer em um paciente, de seleção de uma terapia para um paciente com câncer e de determinação de superexpressão de gene erbb2 em uma célula |
BR112014007569A2 (pt) | 2011-09-30 | 2017-04-18 | Genentech Inc | marcadores de metilação diagnósticos fenótipo epitelial ou mesenquimal e a resposta ao inibidor da quinase de egfr em tumores ou células tumorais |
EP2817028A4 (en) * | 2012-02-22 | 2015-11-04 | Alethia Biotherapeutics Inc | COMMON USE OF A CLUSTERIN INHIBITOR AND EGFR INHIBITOR FOR TREATING CANCER |
CN103408662A (zh) * | 2013-08-15 | 2013-11-27 | 浙江农林大学 | 一种抗蟾皮转胶蛋白-2重组蛋白的鼠抗血清的制备方法 |
US9211314B2 (en) | 2014-04-04 | 2015-12-15 | Biodesix, Inc. | Treatment selection for lung cancer patients using mass spectrum of blood-based sample |
ES2750832T3 (es) * | 2014-07-29 | 2020-03-27 | Wellmarker Bio Co Ltd | Nuevo biomarcador para predecir la sensibilidad al agente dirigido contra egfr y uso del mismo |
KR102406696B1 (ko) * | 2020-06-19 | 2022-06-08 | (주)신테카바이오 | 약물 민감도 판단을 위한 유전자 검출 방법 및 진단용 조성물 |
WO2022255401A1 (ja) * | 2021-06-03 | 2022-12-08 | 国立大学法人 東京大学 | Erk-mapk経路の異常な活性化に伴い発現する疾患マーカー |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4699877A (en) * | 1982-11-04 | 1987-10-13 | The Regents Of The University Of California | Methods and compositions for detecting human tumors |
USRE35491E (en) * | 1982-11-04 | 1997-04-08 | The Regents Of The University Of California | Methods and compositions for detecting human tumors |
US7838216B1 (en) * | 1986-03-05 | 2010-11-23 | The United States Of America, As Represented By The Department Of Health And Human Services | Human gene related to but distinct from EGF receptor gene |
US5015568A (en) * | 1986-07-09 | 1991-05-14 | The Wistar Institute | Diagnostic methods for detecting lymphomas in humans |
US5202429A (en) * | 1986-07-09 | 1993-04-13 | The Wistar Institute | DNA molecules having human BCL-2 gene sequences |
US4968603A (en) * | 1986-12-31 | 1990-11-06 | The Regents Of The University Of California | Determination of status in neoplastic disease |
US5831066A (en) * | 1988-12-22 | 1998-11-03 | The Trustees Of The University Of Pennsylvania | Regulation of bcl-2 gene expression |
US5858678A (en) * | 1994-08-02 | 1999-01-12 | St. Louis University | Apoptosis-regulating proteins |
US5830753A (en) * | 1994-09-30 | 1998-11-03 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof. |
AU716330B2 (en) * | 1995-12-18 | 2000-02-24 | Sugen, Inc. | Diagnosis and treatment of AUR-1 and/or AUR-2 related disorders |
US6716575B2 (en) * | 1995-12-18 | 2004-04-06 | Sugen, Inc. | Diagnosis and treatment of AUR1 and/or AUR2 related disorders |
US5670325A (en) * | 1996-08-14 | 1997-09-23 | Exact Laboratories, Inc. | Method for the detection of clonal populations of transformed cells in a genomically heterogeneous cellular sample |
US5741650A (en) * | 1996-01-30 | 1998-04-21 | Exact Laboratories, Inc. | Methods for detecting colon cancer from stool samples |
US5821082A (en) * | 1996-05-23 | 1998-10-13 | St. Louis University Health Sciences Center | Anti-proliferation domain of a human Bcl-2 and DNA encoding the same |
US6203993B1 (en) * | 1996-08-14 | 2001-03-20 | Exact Science Corp. | Methods for the detection of nucleic acids |
US5952178A (en) * | 1996-08-14 | 1999-09-14 | Exact Laboratories | Methods for disease diagnosis from stool samples |
US6100029A (en) * | 1996-08-14 | 2000-08-08 | Exact Laboratories, Inc. | Methods for the detection of chromosomal aberrations |
US6143529A (en) * | 1996-08-14 | 2000-11-07 | Exact Laboratories, Inc. | Methods for improving sensitivity and specificity of screening assays |
US5928870A (en) * | 1997-06-16 | 1999-07-27 | Exact Laboratories, Inc. | Methods for the detection of loss of heterozygosity |
US6146828A (en) * | 1996-08-14 | 2000-11-14 | Exact Laboratories, Inc. | Methods for detecting differences in RNA expression levels and uses therefor |
US6020137A (en) * | 1996-08-14 | 2000-02-01 | Exact Laboratories, Inc. | Methods for the detection of loss of heterozygosity |
US5861278A (en) * | 1996-11-01 | 1999-01-19 | Genetics Institute, Inc. | HNF3δ compositions |
DE69739105D1 (de) * | 1996-11-20 | 2008-12-24 | Univ Yale | Survivin, ein protein das zelluläre apoptosis hemmt, und dessen modulation |
US5830665A (en) * | 1997-03-03 | 1998-11-03 | Exact Laboratories, Inc. | Contiguous genomic sequence scanning |
US6033893A (en) * | 1997-06-26 | 2000-03-07 | Incyte Pharmaceuticals, Inc. | Human cathepsin |
US6020135A (en) * | 1998-03-27 | 2000-02-01 | Affymetrix, Inc. | P53-regulated genes |
WO1999064626A2 (en) * | 1998-06-06 | 1999-12-16 | Genostic Pharma Limited | Probes used for genetic profiling |
US6998233B2 (en) * | 1998-06-26 | 2006-02-14 | Sunesis Pharmaceuticals, Inc. | Methods for ligand discovery |
US6335155B1 (en) * | 1998-06-26 | 2002-01-01 | Sunesis Pharmaceuticals, Inc. | Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules |
US6919178B2 (en) * | 2000-11-21 | 2005-07-19 | Sunesis Pharmaceuticals, Inc. | Extended tethering approach for rapid identification of ligands |
US6696558B2 (en) * | 1998-09-09 | 2004-02-24 | The Burnham Institute | Bag proteins and nucleic acid molecules encoding them |
US9534254B1 (en) * | 1999-02-02 | 2017-01-03 | Abbott Molecular Inc. | Patient stratification for cancer therapy based on genomic DNA microarray analysis |
US20020039764A1 (en) * | 1999-03-12 | 2002-04-04 | Rosen Craig A. | Nucleic, acids, proteins, and antibodies |
US6960439B2 (en) * | 1999-06-28 | 2005-11-01 | Source Precision Medicine, Inc. | Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles |
US6692916B2 (en) * | 1999-06-28 | 2004-02-17 | Source Precision Medicine, Inc. | Systems and methods for characterizing a biological condition or agent using precision gene expression profiles |
US6710170B2 (en) * | 1999-09-10 | 2004-03-23 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of ovarian cancer |
US6271002B1 (en) * | 1999-10-04 | 2001-08-07 | Rosetta Inpharmatics, Inc. | RNA amplification method |
US6750013B2 (en) * | 1999-12-02 | 2004-06-15 | Protein Design Labs, Inc. | Methods for detection and diagnosing of breast cancer |
US6248535B1 (en) * | 1999-12-20 | 2001-06-19 | University Of Southern California | Method for isolation of RNA from formalin-fixed paraffin-embedded tissue specimens |
EP1276901A2 (en) * | 2000-01-13 | 2003-01-22 | Amsterdam Support Diagnostics B.V. | A universal nucleic acid amplification system for nucleic acids in a sample |
US6322986B1 (en) * | 2000-01-18 | 2001-11-27 | Albany Medical College | Method for colorectal cancer prognosis and treatment selection |
US6618679B2 (en) * | 2000-01-28 | 2003-09-09 | Althea Technologies, Inc. | Methods for analysis of gene expression |
US6759197B2 (en) * | 2000-03-31 | 2004-07-06 | Sir Mortimer B. Davis -- Jewish General Hospital | Microchip arrays of regulatory genes |
JP2004509612A (ja) * | 2000-06-05 | 2004-04-02 | アバロン ファーマシューティカルズ | ガン遺伝子決定および特徴的な遺伝子群を用いた治療用スクリーニング |
US6974667B2 (en) * | 2000-06-14 | 2005-12-13 | Gene Logic, Inc. | Gene expression profiles in liver cancer |
MXPA03000575A (es) * | 2000-07-21 | 2004-12-13 | Global Genomics Ab | Metodos para analisis e identificacion de genes transcritos e impresion dactilar. |
US6582919B2 (en) * | 2001-06-11 | 2003-06-24 | Response Genetics, Inc. | Method of determining epidermal growth factor receptor and HER2-neu gene expression and correlation of levels thereof with survival rates |
US6602670B2 (en) * | 2000-12-01 | 2003-08-05 | Response Genetics, Inc. | Method of determining a chemotherapeutic regimen based on ERCC1 expression |
WO2002068579A2 (en) * | 2001-01-10 | 2002-09-06 | Pe Corporation (Ny) | Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof |
US7776518B2 (en) * | 2001-01-12 | 2010-08-17 | Yale University | Detection of survivin in the biological fluids of cancer patients |
JP4368110B2 (ja) * | 2001-01-12 | 2009-11-18 | エール ユニヴァーシティ | 癌患者の生物学的流体中のサバイビンの検出 |
US20030199685A1 (en) * | 2001-03-12 | 2003-10-23 | Monogen, Inc. | Cell-based detection and differentiation of disease states |
US20040009489A1 (en) * | 2001-09-28 | 2004-01-15 | Golub Todd R. | Classification of lung carcinomas using gene expression analysis |
EP1470247A2 (en) * | 2001-11-05 | 2004-10-27 | Deutsches Krebsforschungszentrum | Novel genetic markers for leukemias |
WO2003040404A1 (en) * | 2001-11-09 | 2003-05-15 | Source Precision Medicine, Inc. | Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles |
US20030198972A1 (en) * | 2001-12-21 | 2003-10-23 | Erlander Mark G. | Grading of breast cancer |
WO2004046386A1 (en) * | 2002-11-15 | 2004-06-03 | Genomic Health, Inc. | Gene expression profiling of egfr positive cancer |
-
2004
- 2004-05-28 WO PCT/US2004/017215 patent/WO2004111273A2/en active Application Filing
- 2004-05-28 EP EP10158352A patent/EP2226396A1/en not_active Withdrawn
- 2004-05-28 AU AU2004248140A patent/AU2004248140A1/en not_active Abandoned
- 2004-05-28 JP JP2006533538A patent/JP2007506442A/ja active Pending
- 2004-05-28 EP EP04753936A patent/EP1636380A2/en not_active Withdrawn
- 2004-05-28 US US10/857,715 patent/US20050164218A1/en not_active Abandoned
- 2004-05-28 CA CA002527321A patent/CA2527321A1/en not_active Abandoned
-
2007
- 2007-12-03 US US11/949,535 patent/US20080318230A1/en not_active Abandoned
-
2009
- 2009-12-11 AU AU2009248449A patent/AU2009248449A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2007506442A5 (ja) | ||
US8198024B2 (en) | Gene expression markers for colorectal cancer prognosis | |
ES2537403T3 (es) | Método para usar la expresión génica para determinar el pronóstico de cáncer de próstata | |
JP6404304B2 (ja) | メラノーマ癌の予後予測 | |
JP2014509189A (ja) | 結腸ガン遺伝子発現シグネチャーおよび使用方法 | |
EP2982986B1 (en) | Method for manufacturing gastric cancer prognosis prediction model | |
EP2780476B1 (en) | Methods for diagnosis and/or prognosis of gynecological cancer | |
KR20180002882A (ko) | 유전자 발현 프로파일 및 유방암에 대한 이의 용도 | |
Tsao et al. | A fast and convenient new technique to detect the therapeutic target, K-ras mutant, from peripheral blood in non-small cell lung cancer patients | |
MX2011006926A (es) | Metodos y medios para categorizar una muestra que comprende celulas de cancer colorrectal. | |
CN101457254B (zh) | 用于肝癌预后的基因芯片和试剂盒 | |
EP1683862B1 (en) | Microarray for assessing neuroblastoma prognosis and method of assessing neuroblastoma prognosis | |
KR20170072685A (ko) | 삼중음성유방암의 아형 분류 방법 | |
Somura et al. | A three-gene predictor for early intrahepatic recurrence of hepatocellular carcinoma after curative hepatectomy | |
KR20230025895A (ko) | 순환 종양 핵산 분자의 다중모드 분석 | |
Shimada et al. | cDNA microarray analysis of esophageal cancer: discoveries and prospects | |
JP2024519082A (ja) | 肝細胞がんのdnaメチル化バイオマーカー | |
WO2023168345A2 (en) | Methylated dna markers and assays thereof for use in detecting colorectal cancer | |
CN113957145A (zh) | m6A相关lncRNA在预测小细胞肺癌预后和化疗反应的应用 |